Inhibition of Prekallikrein for Hereditary Angioedema.
Lauré M FijenMarc A RiedlLaura BordoneJonathan A BernsteinJason RaaschRaffi TachdjianTimothy CraigWilliam R LumryMichael E ManningVeronica J AlexanderKenneth B NewmanAlexey RevenkoBrenda F BakerCharvi NanavatiA Robert MacLeodEugene SchneiderDanny M CohnPublished in: The New England journal of medicine (2022)
Among patients with hereditary angioedema, donidalorsen treatment resulted in a significantly lower rate of angioedema attacks than placebo in this small, phase 2 trial. (Funded by Ionis Pharmaceuticals; ISIS 721744-CS2 ClinicalTrials.gov number, NCT04030598.).